This clinical trial is focused on studying Chronic Obstructive Pulmonary Disease (COPD), a long-term lung condition that makes it hard to breathe. The study is testing a treatment called itepekimab, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins made in a lab that can help the immune system fight diseases. In this study, itepekimab is given as a solution for injection using a pre-filled syringe. The purpose of the study is to evaluate how well itepekimab works compared to a placebo in reducing the number of flare-ups, or exacerbations, in people with moderate-to-severe COPD who used to smoke.

Participants in the study will receive either itepekimab or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure the results are not biased. The study will last for about a year, during which participants will receive regular injections and attend scheduled visits to monitor their health and the effects of the treatment. The researchers will be looking at how often participants experience COPD exacerbations, which are episodes where symptoms suddenly get worse and may require additional treatment.

Throughout the study, various health assessments will be conducted to ensure the safety and well-being of the participants. These assessments will include checking lung function, monitoring any side effects, and evaluating overall respiratory symptoms. The study aims to provide valuable information on the effectiveness and safety of itepekimab as a potential treatment for COPD, which could lead to improved management of this challenging condition.